Bentley, Sian;
Cheong, Jamie;
Gudka, Nikesh;
Makhecha, Sukeshi;
Hadjisymeou-Andreou, Simone;
Standing, Joseph F;
(2023)
Therapeutic drug monitoring-guided dosing for pediatric cystic fibrosis patients: recent advances and future outlooks.
Expert Review of Clinical Pharmacology
, 16
(8)
pp. 715-726.
10.1080/17512433.2023.2238597.
Preview |
Text
Standing_040723 Revised Paed CF PK-TDM.pdf Download (442kB) | Preview |
Abstract
Introduction: Medicine use in children with cystic fibrosis (CF) is complicated by inconsistent pharmacokinetics at variance with the general population, a lack of research into this and its effects on clinical outcomes. In the absence of established dose regimens, therapeutic drug monitoring (TDM) is a clinically relevant tool to optimize drug exposure and maximize therapeutic effect by the bedside. In clinical practice though, use of this is variable and limited by a lack of expert recommendations. Areas covered: We aimed to review the use of TDM in children with CF to summarize recent developments, current recommendations, and opportunities for future directions. We searched PubMed for relevant publications using the broad search terms “cystic fibrosis” in combination with the specific terms ”therapeutic drug monitoring (TDM)” and ”children.” Further searches were undertaken using the name of identified drugs combined with the term ”TDM.” Expert opinion: Further research into the use of Bayesian forecasting and the relationship between exposure and response is required to personalize dosing, with the opportunity for the development of expert recommendations in children with CF. Use of noninvasive methods of TDM has the potential to improve accessibility to TDM in this cohort.
| Type: | Article |
|---|---|
| Title: | Therapeutic drug monitoring-guided dosing for pediatric cystic fibrosis patients: recent advances and future outlooks |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1080/17512433.2023.2238597 |
| Publisher version: | https://doi.org/10.1080/17512433.2023.2238597 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | >, ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS, Antimicrobials, children, CHILDREN, CLINICAL-TRIALS, cystic fibrosis, cystic fibrosis transmembrane regulator (CFTR), HIGH-DOSE IBUPROFEN, ITRACONAZOLE, Life Sciences & Biomedicine, PHARMACODYNAMICS, pharmacokinetics, Pharmacology & Pharmacy, POPULATION PHARMACOKINETICS, PSEUDOMONAS-AERUGINOSA, PULMONARY EXACERBATIONS, Science & Technology, therapeutic drug monitoring, TOBRAMYCIN TREATMENT |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Infection, Immunity and Inflammation Dept |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10204115 |
Archive Staff Only
 |
View Item |
